Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The drug, known as Yeztugo, is the first and only twice-yearly option available in the U.S. for people who need or want PrEP, Gilead said Wednesday. Just under 100% of patients who received the drug ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...

Restrictions around sexually active gay and bisexual men donating blood and plasma are being loosened in a new world-leading ...

But the question of whether HIV-negative patients should be disallowed from receiving an organ from an HIV-positive donor has not been adequately explored. In this essay, we will discuss the ...

Shahin Davoudpour, PhD, MA, MA, discusses the challenges associated with access to and persistence with pre-exposure ...

A doctor at the Edo hospital who pleaded anonymity said, “We had to run thorough screening on the couple. Results confirmed ...

In this review, we examine the effects of HIV‐associated inflammation and immune activation on the cardiovascular system with a focus on atherosclerotic CVD and discuss existing and proposed ...

A new study published in the Journal of Neuroimmune Pharmacology finds that regular marijuana use may help normalize abnormal ...

With 85% 10-year survival reported in HIV-positive transplant recipients in Spain, the country is now moving toward policy reform to expand donor eligibility.

“Before giving birth, I was given Nevirapine,” Maame Esi explains, adding that her child was born HIV-negative, thanks to timely intervention and medical support. She could not breastfeed due to the ...